FDA puts injection therapy COYA 302 on fast track for treating ALS
WHY IT MATTERS
ALS patients now have a potential new treatment option moving through FDA review faster than standard timelines, which could mean access to COYA 302 years sooner if clinical trials continue to show benefit.
The FDA has given special fast-track status to COYA 302, an injection treatment being developed by Coya Therapeutics for ALS (a disease that weakens muscles over time). Early testing showed it might slow down how quickly the disease gets worse in a small group of patients. Fast-track status means the FDA will review this treatment more quickly than usual to help get it to patients faster.
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial to slow disease progression in a small number of patients — has been awarded fast track status by the U.S. Food and Drug Administration (FDA). That designation is intended to accelerate the development and review of therapies […] The post FDA puts injection therapy COYA 302 on fast track for treating ALS appeared first on ALS News Today .
ASK YOUR DOCTOR
Talk to your ALS specialist about whether you might be eligible for COYA 302 clinical trials and ask them to monitor this therapy's development progress.